2-azido-1-(3-bromophenyl)ethan-1-ol | 943911-72-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-azido-1-(3-bromophenyl)ethan-1-ol
• 英文别名: 2-azido-1-(3-bromophenyl)ethanol；2-Azido-1-(3-bromo-phenyl)-ethanol
• CAS: 943911-72-6
• 化学式: C₈H₈BrN₃O
• 分子量: 242.075
• InChiKey: UCPQHFRJCZVWHZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  34.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-azido-1-(3-bromophenyl)ethan-1-ol 在 水 、 三苯基膦 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 以85%的产率得到2-氨基-1-(3-溴苯基)乙醇
  参考文献：
  名称：

  WO2007/78523

  摘要：

  公开号：
• 作为产物：
  描述：

  [2-bromo-1-(3-bromo-phenyl)-ethoxy]-trimethyl-silane 在 sodium azide 、 水 、 碳酸氢钠 作用下， 以 二甲基亚砜 为溶剂， 反应 22.0h， 以83%的产率得到2-azido-1-(3-bromophenyl)ethan-1-ol
  参考文献：
  名称：

  WO2007/78523

  摘要：

  公开号：

文献信息

• Oxazolidinone Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators
  申请人：Slassi Abdelmalik

  公开号：US20090012089A1

  公开（公告）日：2009-01-08

  The present invention is directed to compounds of Formula I: Wherein R 1 , R 2 , Y, m and n are further defined in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.

  本发明涉及式I的化合物：其中R1、R2、Y、m和n在描述中进一步定义。本发明还涉及制备该化合物的过程，以及用于制备的新中间体，包含该化合物的药物组合物，以及该化合物在治疗中的使用。
• Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators
  申请人：Slassi Abdelmalik

  公开号：US20070275966A1

  公开（公告）日：2007-11-29

  The present invention is directed to compounds of Formula I: Wherein R 1 , R 2 , Y, m and n are further defined in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.

  本发明涉及公式I的化合物：其中R1、R2、Y、m和n在描述中进一步定义。本发明还涉及制备该化合物的过程，以及用于制备的新中间体，包含该化合物的制药组合物，以及该化合物在治疗中的使用。
• Photochemical Mn-Mediated Generation of Azide Radicals for Improvement of Alkene Hydroxyazidation
  作者：Chen-Xi Xia、Ziyang Li、Ruyi Ye、Zhao-Juan Wu、Yue Ren、Kuai Wang、Ling-Guo Meng

  DOI：10.1021/acs.orglett.4c00911

  日期：——

  reagents to improve the chemoselectivity. To overcome the above problems, we present a photochemical hydroxyazidation of alkenes via Mn-mediated ligand-to-metal charge transfer (LMCT) in O2, which activates N3– to •N3 and incorporates O2 to be used as an oxygen source in the hydroxyazidation products. Broad alkene range and step-economy chemistry for the hydroxyazidation transformation were also demonstrated

  最先进的烯烃羟基叠氮化策略，产生β-叠氮醇和β-叠氮过氧化物的混合物，必须依靠膦试剂来提高化学选择性。为了克服上述问题，我们提出了一种通过 O 2中锰介导的配体到金属电荷转移 (LMCT) 进行烯烃的光化学羟基叠氮反应，将 N 3 –活化为•N 3并结合 O 2用作氧来源为羟基叠氮化产物。还证明了羟基叠氮化转化的广泛烯烃范围和步骤经济化学。
• Non-enzymatic kinetic resolution of 1,2-azidoalcohols using a planar-chiral DMAP derivative catalyst
  作者：Laura Mesas-Sánchez、Alba E. Díaz-Álvarez、Peter Dinér

  DOI：10.1016/j.tet.2012.10.077

  日期：2013.1

  Optically pure 1,2-azidoalcohols are widely used as precursors for other high value organic products. A non-enzymatic kinetic resolution procedure for the stereoselective synthesis of chiral 1,2-azidoalcohols from the readily available racemic counterparts has been developed, employing a planar-chiral DMAP derivative catalyst. Following this procedure, a range of aromatic 1,2-azidoalcohols was obtained in good selectivities (up to S=45) and high enantiomeric excess (up to 99% ee). (c) 2012 Elsevier Ltd. All rights reserved.
• A Series of Potent and Selective, Triazolylphenyl-Based Histone Deacetylases Inhibitors with Activity against Pancreatic Cancer Cells and <i>Plasmodium falciparum</i>
  作者：Yufeng Chen、Miriam Lopez-Sanchez、Doris N. Savoy、Daniel D. Billadeau、Geoffrey S. Dow、Alan P. Kozikowski

  DOI：10.1021/jm701606b

  日期：2008.6.1

  The discovery of the rules governing the inhibition of the various HDAC isoforms is likely to be key to identifying improved therapeutics that act as epigenetic modulators of gene transcription. Herein we present results on the modification of the CAP region of a set of triazolylphenyl-based HDACIs, and show that the nature of substitution on the phenyl ring plays a role in their selectivity for HDAC1 versus HDAC6, with low to moderate selectivity (2-51-fold) being achieved. In light of the valuable selectivity and potency that were identified for the triazolylphenyl ligand 6b in the inhibition of HDAC6 (IC50 = 1.9 nM), this compound represents a valuable research tool and a candidate for further chemical modifications. Lastly, these new HDACIs were studied for both their anticancer and antimalarial activity, which serve to validate the superior activity of the HDACI 10c.